A detailed history of Ameriprise Financial Inc transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 284,390 shares of FATE stock, worth $915,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares
284,390
Previous 251,649 13.01%
Holding current value
$915,735
Previous $941,000 121.79%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.54 - $8.35 $115,903 - $273,387
32,741 Added 13.01%
284,390 $2.09 Million
Q4 2023

Feb 14, 2024

SELL
$1.65 - $3.94 $39,340 - $93,941
-23,843 Reduced 8.65%
251,649 $941,000
Q3 2023

Nov 14, 2023

BUY
$2.02 - $5.04 $55,335 - $138,065
27,394 Added 11.04%
275,492 $584,000
Q2 2023

Aug 14, 2023

BUY
$4.76 - $6.59 $814,145 - $1.13 Million
171,039 Added 221.96%
248,098 $1.18 Million
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $246,907 - $647,550
58,233 Added 309.32%
77,059 $439,000
Q4 2022

Feb 14, 2023

SELL
$9.86 - $23.83 $653,037 - $1.58 Million
-66,231 Reduced 77.87%
18,826 $189,000
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $109,050 - $186,898
5,183 Added 6.49%
85,057 $1.91 Million
Q2 2022

Aug 15, 2022

BUY
$17.78 - $42.39 $173,212 - $412,963
9,742 Added 13.89%
79,874 $1.98 Million
Q1 2022

May 16, 2022

SELL
$29.67 - $60.28 $13.1 Million - $26.6 Million
-441,520 Reduced 86.29%
70,132 $2.72 Million
Q4 2021

Feb 14, 2022

SELL
$47.84 - $64.34 $13.6 Million - $18.3 Million
-285,019 Reduced 35.78%
511,652 $29.9 Million
Q3 2021

Nov 15, 2021

BUY
$59.27 - $95.73 $7.6 Million - $12.3 Million
128,223 Added 19.18%
796,671 $47.2 Million
Q2 2021

Aug 16, 2021

BUY
$67.25 - $92.52 $3.14 Million - $4.32 Million
46,743 Added 7.52%
668,448 $58 Million
Q1 2021

May 17, 2021

BUY
$72.16 - $117.4 $25.8 Million - $41.9 Million
357,066 Added 134.93%
621,705 $51.3 Million
Q4 2020

Feb 12, 2021

SELL
$38.09 - $100.95 $2.83 Million - $7.49 Million
-74,186 Reduced 21.9%
264,639 $24.1 Million
Q3 2020

Nov 16, 2020

SELL
$30.41 - $40.5 $463,235 - $616,936
-15,233 Reduced 4.3%
338,825 $13.5 Million
Q2 2020

Aug 14, 2020

SELL
$20.21 - $35.23 $3.05 Million - $5.32 Million
-150,968 Reduced 29.89%
354,058 $12.1 Million
Q1 2020

May 15, 2020

SELL
$17.28 - $31.88 $25 Million - $46.1 Million
-1,445,247 Reduced 74.1%
505,026 $11.2 Million
Q4 2019

Feb 14, 2020

BUY
$13.39 - $20.73 $5.99 Million - $9.28 Million
447,711 Added 29.8%
1,950,273 $38.2 Million
Q3 2019

Nov 14, 2019

BUY
$15.47 - $22.5 $12.4 Million - $18 Million
799,286 Added 113.65%
1,502,562 $23.3 Million
Q2 2019

Aug 14, 2019

BUY
$15.61 - $20.44 $11 Million - $14.4 Million
703,276 New
703,276 $14.3 Million
Q2 2018

Aug 14, 2018

SELL
$9.16 - $13.48 $809,414 - $1.19 Million
-88,364 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$6.3 - $13.77 $556,693 - $1.22 Million
88,364 New
88,364 $862,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $312M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.